In the hormone-dependent prostate inflammation model induced by implantation of slow-releasing pellets (50 mg testosterone and 5 mg estradiol) to Noble male rats, intragastric administration of Afala at a dose of 7.5 ml/kg for 18 weeks reduced the number of inflamed prostatic acini. The effect of afala was comparable with that of antiestrogen ICI 182,780 (3 mg/kg subcutaneously twice a week for 18 weeks). Prolonged treatment with hormones in high doses induced severe inflammation of the prostate tissue, which was not terminated by the test preparations. As differentiated from the antiestrogen ICI 182,780, afala did not induce body weight gain and decrease in pituitary weight in experimental animals in comparison with the control group.

2009-08-01·Bulletin of Experimental Biology and Medicine4区 · 医学

Clinical Use of Afala in the Therapy of Chronic Prostatitis

4区 · 医学

Article

作者: Tkachuk, V N

The efficiency of afala in the therapy of chronic abacterial prostatitis was demonstrated. The preparation considerably improved urodynamics, reduced pain syndrome and inflammation, decreased prostate volume, improved patient's quality of life, and restored microcirculation in the prostate. No changes in blood, urine, and ECG parameters were noted. No side effects requiring afala withdrawal were recorded.

2009-08-01·Bulletin of Experimental Biology and Medicine4区 · 医学

Experience of Long-Term Afala Treatment in Benign Prostatic Hyperplasia

4区 · 医学

Article

作者: Gudkov, A V

The use of ultralow doses of antibodies to prostate-specific antigen (afala) for long-term treatment of benign prostatic hyperplasia in patients with moderate symptoms rapidly and effectively reduces irritative and obstructive symptoms, significantly decreases residual urine volume, and increases the rate of urination. Afala therapy is indicated for patients with stage I-II benign prostatic hyperplasia of moderately pronounced symptoms.

100 项与 Afala 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
前列腺癌	俄罗斯	Materia Medica Holding Research And Production Company	2014-01-01
前列腺炎	俄罗斯	Materia Medica Holding Research And Production Company	2014-01-01